title: Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function.
abstract: OBJECTIVE
  To evaluate the effects of PHA-543613 (α7-nAChR agonist) and galantamine (acetylcholinesterase inhibitor (AChEI)) on recognition memory and neurovascular coupling (NVC) response in beta-amyloid (Aβ) 25-35-treated mice.
  
  
  METHODS
  PHA-543613 (1 mg/kg, i.p.), and galantamine (3 mg/kg, s.c.), effects were tested in Aβ25-35 mice model of AD. α7-nAChR antagonist, methyllycaconitine (MLA) (1 mg/kg, i.p.), was used for evaluation of receptor blockade effects. Recognition memory in animals was assessed by the novel object recognition (NOR) task. NVC response was analyzed by laser-doppler flow meter in barrel cortex by whisker stimulation method.
  
  
  RESULTS
  Both, PHA-543613 and galantamine improve recognition memory in Aβ-treated animals. However, the advantageous effects of PHA-543613 were significantly higher than galantamine. Also, pretreatment with MLA reversed both galantamine and PHA-543613 effects on NOR. Impaired NVC response in AD animals was improved by PHA-543613 and galantamine. However, MLA pretreatment disrupts this function.
  
  
  CONCLUSIONS
  Activation of α7-nAChR improved recognition memory possible through enhancement of neurovascular response in Alzheimer's disease in animals.
authors.affiliation: Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Saeed
authors.initials: S
authors.lastname: Sadigh-Eteghad
authors.affiliation: Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Javad
authors.initials: J
authors.lastname: Mahmoudi
authors.affiliation: Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Shirin
authors.initials: S
authors.lastname: Babri
authors.affiliation: Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Talebi
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000503:physiopathology; D016229:Amyloid beta-Peptides; D000818:Animals; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D004195:Disease Models, Animal; D005702:Galantamine / Q000494:pharmacology*; D017078:Laser-Doppler Flowmetry; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy* / Q000503:physiopathology; D008807:Mice, Inbred BALB C; D009483:Neuropsychological Tests; D000069336:Neurovascular Coupling / Q000187:drug effects* / Q000502:physiology; D010446:Peptide Fragments; D011812:Quinuclidines / Q000494:pharmacology*; D021641:Recognition, Psychology / Q000187:drug effects; D015203:Reproducibility of Results; D013997:Time Factors; D016896:Treatment Outcome; D064569:alpha7 Nicotinic Acetylcholine Receptor / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002800:Cholinesterase Inhibitors; C513163:N-(1-azabicyclo(2.2.2)oct-3-yl)furo(2,3-c)pyridine-5-carboxamide; D010446:Peptide Fragments; D011812:Quinuclidines; D064569:alpha7 Nicotinic Acetylcholine Receptor; C074636:amyloid beta-protein (25-35); D005702:Galantamine